Pfizer may be eyeing deal with Israeli biotech

Wed. November 04, 2009; Posted: 08:11 PM

Look up the PowerRating of PFE and see how it has performed over the past week as well as the current proprietary PowerRating.

Nov 03, 2009 (The Day - McClatchy-Tribune Information Services via COMTEX) -- PFE | Quote | Chart | News | PowerRating -- Pfizer Inc. is wooing up-and-coming Israeli biotech Protalix Biotherapeutics for a possible buyout or partnership, the financial newspaper TheMarker reported Monday.

Protalix shares, which have quintupled in price already this year thanks to the company's development of a promising new Gaucher's disease therapy, rose another 7 percent in early trading Monday.

Protalix previously had been linked to reports of a possible acquisition by Teva Pharmaceutical Industries Ltd. Protalix and Teva have deep connections, with Teva chairman Eli Hurvitz serving as chairman of Protalix and Teva vice chairman Phillip Frost owning nearly 10 percent of Protalix, according to the Israeli business site Globes Online.

And Protalix is looking for a deal. Chief Executive David Aviezer has said he expects a partnership to be lined up by the end of the year, according to TheMarker.

The Israeli newspaper said Protalix's Uplyso drug to treat Gaucher's disease -- a buildup of fatty substances in some of the body's most vital organs -- apparently caught the eye of Pfizer, which is on the hunt for new compounds as some of its blockbuster medications near patent expirations.

Uplyso in the past few months has won Food and Drug Administration go-aheads for both fast-track approval and so-called "orphan drug status," which lowers the bar for a new drug application based on its being the only known therapy.

TheMarker reported that a delegation from Pfizer visited Protalix's facilities last week as it sought a development deal or buyout.

Pfizer does not comment on reports of possible acquisitions, labeling them "rumors and speculation" until completed.

To see more of The Day, or to subscribe to the newspaper, go to
http://www.theday.com. Copyright (c) 2009, The Day, New London, Conn.
Distributed by McClatchy-Tribune Information Services. For reprints, email
tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax
to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave.,
Suite 303, Glenview, IL 60025, USA.

For full details on Pfizer Inc (PFE) click here. Pfizer Inc (PFE) has Short Term PowerRatings of 6. Details on Pfizer Inc (PFE) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

Tax Relief Bank Levy Wage Garnishment

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.